𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HMGA2 overexpression in non-small cell lung cancer

✍ Scribed by Britta Meyer; Siegfried Loeschke; Anke Schultze; Thomas Weigel; Martin Sandkamp; Torsten Goldmann; Ekkehard Vollmer; Jörn Bullerdiek

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
318 KB
Volume
46
Category
Article
ISSN
0899-1987

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Lung cancer is still the leading cause of death from cancer worldwide primarily because of the fact that most lung cancers are diagnosed at advanced stages. Overexpression of the high mobility group protein HMGA2 has been observed in a variety of malignant tumors and often correlates with poor prognosis. Herein, HMGA2 expression levels were analyzed in matching cancerous and non‐cancerous lung samples of 17 patients with adenocarcinoma (AC) and 17 patients with squamous cell carcinoma (SCC) with real‐time quantitative RT‐PCR (qRT‐PCR). Transcript levels were compared to results obtained by immunohistochemistry (IHC). HMGA2 expression was detectable by qRT‐PCR in all samples tested and varied from 5422 to 16 991 545 copies per 250 ng total RNA in the carcinoma samples and from 289 to 525 947 copies in the non‐cancerous tissue samples. In 33/34 non‐small cell lung cancer (NSCLC) samples tested, an overexpression of HMGA2 was revealed with statistically highly significant differences between non‐neoplastic and tumor samples for both AC (P < 0.0001) as well as for SCC (P < 0.0001). Expression varies strongly and is increased up to 911‐fold for AC and up to 2504‐fold for SCC, respectively, with statistically significant higher increase in SCC (P < 0.05). The results presented herein indicate that HMGA2 overexpression is a common event in NSCLC and could serve as molecular marker for lung cancer. © 2007 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Contemporary brachytherapy approaches in
Contemporary brachytherapy approaches in non–small-cell lung cancer
✍ Hilaris, Basil S.; Mastoras, Dina A. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Brachytherapy has the ability to deliver a higher tumor dose compared to external beam irradiation, while sparing normal tissue outside the tumor; it is the most effective means of delivering conformal radiation and can be tailored to clinical circumstances, either at open surgery or in an ambulator

Tumor angiogenesis of non–small cell lun
Tumor angiogenesis of non–small cell lung cancer
✍ Noriharu Shijubo; Hiroshi Kojima; Manabu Nagata; Takashi Ohchi; Akihiro Suzuki; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Abstract Lung cancer is one of the commonest causes of cancer death in developed countries. Recent evidence suggests that angoigenesis is related to poor prognosis in many solid tumors including non–small cell lung cancer (NSCLC). Angiogenesis is regulated by a complex interaction among growth f

Adjuvant therapy of non-small cell lung
Adjuvant therapy of non-small cell lung cancer
✍ E. Carmack Holmes 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 1 views

One hundred and forty thousand patients in the United States will develop lung cancer annually. About one half of these will have disease confined to the thorax with no clinical evidence of dissemination (Figure 1). A relatively high proportion of these patients will actually have disease that can b

Aberrant methylation of TMS1 in small ce
Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer
✍ Arvind Virmani; Asha Rathi; Kenji Sugio; Ubaradka G. Sathyanarayana; Shinichi To 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 320 KB 👁 2 views

## Abstract __TMS1__ (target of methylation‐induced silencing) is a CpG island‐associated gene that functions in the regulation of apoptosis and encodes a caspase recruitment domain, a recently described motif found in apoptotic signaling molecules. Recent evidence suggests that silencing of genes

Multidrug resistance-associated protein
Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC)
✍ Hélène Doubre; Danièle Césari; Alexa Mairovitz; Cécile Bénac; Sandra Chantot-Bas 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 227 KB 👁 1 views

Resistance to chemotherapy is intrinsically present in most nonsmall-cell lung carcinomas (NSCLC). No parameter has yet been determined to predict the response to chemotherapy. However, MRP1 (multidrug resistance-associated protein) is suspected to play an important role in resistance to treatment.